Radiolabeled Glass Beads Used for Treating Patients With Primary Liver Cancer When Surgery is Not an Option
A Humanitarian Device Exemption Use Protocol of TheraSphere for Treatment of Unresectable Hepatocellular Carcinoma
Sponsor: Boston Scientific Corporation
Listed as NCT00740753, this NA trial focuses on Hepatoma and Liver Cancer and remains completed. Sponsored by Boston Scientific Corporation, it has been updated 12 times since 2004, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Oct 2022 — Jul 2024 [monthly]
Completed NA
-
Jun 2021 — Oct 2022 [monthly]
Completed NA
Status: Enrolling By Invitation → Completed
-
Jan 2021 — Jun 2021 [monthly]
Enrolling By Invitation NA
▶ Show 7 earlier versions
-
Sep 2020 — Jan 2021 [monthly]
Enrolling By Invitation NA
-
Apr 2020 — Sep 2020 [monthly]
Enrolling By Invitation NA
-
Sep 2019 — Apr 2020 [monthly]
Enrolling By Invitation NA
-
Mar 2019 — Sep 2019 [monthly]
Enrolling By Invitation NA
-
Jun 2018 — Mar 2019 [monthly]
Enrolling By Invitation NA
-
Feb 2017 — Jun 2018 [monthly]
Enrolling By Invitation NA
-
Jan 2017 — Feb 2017 [monthly]
Enrolling By Invitation NA
First recorded
Aug 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boston Scientific Corporation
- OHSU Knight Cancer Institute
- Oregon Health and Science University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.